Selective targeting of bioengineered platelets to prostate cancer vasculature: new paradigm for therapeutic modalities

Journal of Cellular and Molecular Medicine
Viviana P MontecinosGary J Smith

Abstract

Androgen deprivation therapy (ADT) provides palliation for most patients with advanced prostate cancer (CaP); however, greater than 80% subsequently fail ADT. ADT has been indicated to induce an acute but transient destabilization of the prostate vasculature in animal models and humans. Human re-hydrated lyophilized platelets (hRL-P) were investigated as a prototype for therapeutic agents designed to target selectively the tumour-associated vasculature in CaP. The ability of hRL-P to bind the perturbed endothelial cells was tested using thrombin- and ADP-activated human umbilical vein endothelial cells (HUVEC), as well as primary xenografts of human prostate tissue undergoing acute vascular involution in response to ADT. hRL-P adhered to activated HUVEC in a dose-responsive manner. Systemically administered hRL-P, and hRL-P loaded with super-paramagnetic iron oxide (SPIO) nanoparticles, selectively targeted the ADT-damaged human microvasculature in primary xenografts of human prostate tissue. This study demonstrated that hRL-P pre-loaded with chemo-therapeutics or nanoparticles could provide a new paradigm for therapeutic modalities to prevent the rebound/increase in prostate vasculature after ADT, inhibiting the transition to ...Continue Reading

References

Nov 18, 1971·The New England Journal of Medicine·J Folkman
Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·M S ReadK M Brinkhous
Jun 11, 1998·Topics in Magnetic Resonance Imaging : TMRI·O ClémentG Frija
Nov 25, 2000·British Journal of Haematology·T H FischerM S Read
Dec 12, 2002·Hematology·Thomas H FischerMarjorie S Read
May 22, 2003·The American Journal of Pathology·Harold F Dvorak
Nov 2, 2006·Transfusion·Thomas H FischerMarjorie S Read
Mar 17, 2007·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·Arthur P Bode, Thomas H Fischer
Feb 11, 2009·The Prostate·Carl MorrisonJames L Mohler
Jul 16, 2010·International Journal of Radiation Oncology, Biology, Physics·Roberto AlonziPeter J Hoskin
Aug 12, 2010·American Journal of Physiology. Endocrinology and Metabolism·Alejandro GodoyGary J Smith
Mar 3, 2011·Nature Reviews. Clinical Oncology·John M L Ebos, Robert S Kerbel

❮ Previous
Next ❯

Citations

May 18, 2016·Experimental Biology and Medicine·Seema Nandi, Ashley C Brown
Dec 8, 2016·Macromolecular Bioscience·Samagya BanskotaAshutosh Chilkoti
Jan 23, 2021·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Duoyi ZhaoXuesi Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft
Fluorescence

Software Mentioned

IonSpec®

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Biomaterial Engineering

Advances in biomaterial engineering have permitted the development of sophisticated drug-releasing materials with a biomimetic 3D support that allow a better control of the microenvironment of transplanted cells. Here is the latest research.